Skip to content

The General Breathing Record Study

An Observational Proof-of-concept Study to Explore the Waveform Characteristics of Tidal Breathing Carbon Dioxide (CO2), Measured Using the N-Tidal C™ Device, in Different Breathing Conditions.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03356288
Acronym
GBRS
Enrollment
70
Registered
2017-11-29
Start date
2017-08-09
Completion date
2018-07-04
Last updated
2018-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Breathlessness, Heart Failure, Motor Neuron Disease, Pneumonia, Vocal Cord Dysfunction

Keywords

Capnography, Diagnosis. Breathlessness, Exacerbations, Device

Brief summary

This study will test the use of a new handheld device (called the N-Tidal C), that measures a person's tidal breath carbon dioxide, in diagnosing the cause of someone's breathlessness. It will also evaluate whether this device can detect when a person's breathing problem is getting worse.

Detailed description

When a person breathes out, they exhale carbon dioxide (CO2). The CO2 levels in breath change as they breathe out and this makes a specific pattern, or waveform. This waveform can tell a clinician a lot about the underlying health of a person. There are disease specific CO2 waveforms for common breathing conditions such as Asthma and Chronic Obstructive Pulmonary Disease (COPD). However up until this point there has been no accurate and non-invasive method of measuring the tidal breath CO2 waveform. This study will test the N-Tidal C, a new handheld device that accurately measures this waveform, and whether it can differentiate different causes of breathlessness; namely asthma, heart failure, pneumonia, breathing pattern disorders and motor neurone disease.

Interventions

None listed

Sponsors

Innovate UK
CollaboratorOTHER_GOV
TidalSense
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Asthma Cohort: * A confirmed clinical diagnosis of asthma for ≥ 6months * Moderate to severe asthma defined as British Thoracic Society stages 3-5 * 2 or more exacerbations in the previous 12 months with at least 1 exacerbation within the last 6 months. * Exacerbation free for 2 weeks (defined as no increased dose or course of oral corticosteroids or antibiotics). Breathing Pattern Disorder Cohort * A Clinical diagnosis of a Breathing Pattern Disorder (BPD) Chronic heart failure Cohort: * A confirmed clinical diagnosis of chronic heart failure with both of the following: 1. A Left Ventricular Ejection Fraction \<40% on most recent imaging within the last 12 months. 2. New York Heart Association Class 2-4 * Admitted with an acute decompensation of their heart failure to hospital within the last 6 months Motor Neurone Disease Cohort: * A confirmed clinical diagnosis of Motor Neurone Disease * Forced Vital Capacity (FVC) of less than 60% of predicted, sleep disordered breathing or daytime hypercapnia. * Established on Home Non-Invasive Ventilation. Pneumonia Cohort: * A confirmed clinical diagnosis of Pneumonia supported by evidence of consolidation on a chest X-ray (CXR) or computed tomography (CT) imaging. Healthy Cohort: * No known history of lung, cardiac or neuromuscular disease (defined as no current clinical diagnosis of, or be receiving treatment for, a lung, cardiac or neuromuscular disease). A Body Mass Index of less than 40. A Non-smoker, or an ex-smoker with less than a 5 pack year history.

Exclusion criteria

* Known other lung, chest wall, neuromuscular, cardiac or other comorbidity or abnormality that would affect spirometry and/or other measures of lung function or Tidal Breath Carbon Dioxide measurements. * In the opinion of the clinical investigator, the participant would have difficulty completing the study procedures consistently over the course of 6 months.

Design outcomes

Primary

MeasureTime frame
The tidal breathing carbon dioxide waveform for each of the breathing conditions as measured by the N-Tidal C device12 months

Secondary

MeasureTime frameDescription
Disease Control in asthma patients12 monthsThe Asthma Control Questionnaire Score for the Asthma patients
Disease Improvement in Breathing Pattern Disorder patients12 monthsThe Nijmegen Questionnaire Score
Disease severity in the pneumonia patients2 daysThe CURB-65 Score
Change in the Tidal Breathing carbon dioxide waveform over timeChange measures - baseline to 6 monthsChange in the tidal breathing carbon dioxide waveform, in each disease, over the 6 months.
Hypercapnia in the motor neurone disease patients12 monthsThe level of partial pressure carbon dioxide (pCO2)
Usability of the N-Tidal C deviceChange measures - baseline to 6 monthsMeasured by how frequently the patients remember to use the N-Tidal C device over 6 months
Acceptability of the N-Tidal C device12 monthsMeasured by a questionnaire of the participants experience of the device at the end of the study
Disease severity in heart failure patients12 monthsThe Trans Thoracic Echocardiogram (TTE) result

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026